Fire Needle Therapy on Plaque Psoriasis With Blood Stasis Syndrome
NCT03953885 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 92
Last updated 2019-05-17
Summary
This study was designed as a multicenter, randomized, single blinded and placebo-controlled clinical trial. The aim of the study is to evaluate the clinical efficacy, safety and control of recurrence rate of plaque psoriasis with blood stasis syndrome, after treated with fire needle therapy.
Conditions
Interventions
- OTHER
-
Fire needle
1. Participants wear eye masks and fully expose the lesions. After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation. After selecting an acupuncture needle with a specification of 0.4\*40mm and ignites the alcohol lamp, the operator continuously moves the needle from the needle root to the needle tip to burn the red needle to disinfect the needle in the outer flame of the alcohol lamp. 2. The operator ignites the alcohol lamp, and burns the needle tip and the needle body to the outer flame of the alcohol lamp until it is completely red (the length of the needle burning red is determined by the acupuncture depth), and then rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm.
- OTHER
-
Fire needle Placebo
1. Participants wear eye masks and fully expose the lesions (no lesions on the head and face, external genitalia and skin folds). After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation, then selects an acupuncture needle with a specification of 0.4\*40mm to prepare for operation. 2. The operator rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm.
Sponsors & Collaborators
-
Shaanxi Provincial Hospital of Traditional Chinese Medicine
collaborator UNKNOWN -
The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine
collaborator OTHER -
Shijiazhuang Hospital of Traditional Chinese Medicine
collaborator UNKNOWN -
Heilongjiang University of Chinese Medicine
collaborator OTHER -
Shanghai Yueyang Integrated Medicine Hospital
lead OTHER
Principal Investigators
-
Jia Zhou · Department of dermatology, Shanghai Yueyang Integrated Medicine Hospital, Shanghai
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-06-01
- Primary Completion
- 2021-12-31
- Completion
- 2021-12-31
Countries
- China
Study Locations
More Related Trials
-
Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases
NCT03388255 ·Status: TERMINATED ·Phase: PHASE4
-
Fresolimumab In Systemic Sclerosis
NCT01284322 ·Status: COMPLETED ·Phase: PHASE1
-
A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy
NCT00936546 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome
NCT02165111 ·Status: COMPLETED ·Phase: PHASE3
-
Methods Validation Assessment for Study of Inflammatory Skin Disease
NCT03796806 ·Status: COMPLETED
-
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
NCT02396238 ·Status: COMPLETED ·Phase: NA
-
Autologous Adipose Tissue in the Treatment of Systemic Sclerosis Digital Ulcers
NCT03406988 ·Status: UNKNOWN ·Phase: NA
-
Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
NCT02349009 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Platelet Gel in Systemic Sclerosis
NCT00463125 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
NCT02228850 ·Status: COMPLETED ·Phase: PHASE2
-
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
NCT01651143 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of High Dose Methylprednisolone on Nailfold in Early Systemic Sclerosis ( SSc )
NCT03059979 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis
NCT02558543 ·Status: TERMINATED ·Phase: PHASE2
-
China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project
NCT05316805 ·Status: RECRUITING
-
A Prospective Cohort Study on Primary Cutaneous Amyloidosis
NCT06998875 ·Status: RECRUITING ·Phase: PHASE4
-
Pirfenidone as Treatment of Skin Fibrosis in Systemic Sclerosis
NCT03068234 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
NCT06375005 ·Status: RECRUITING ·Phase: PHASE2
-
Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
NCT03398837 ·Status: TERMINATED ·Phase: PHASE3
-
Skin Denervation in Systemic Lupus Erythematosus
NCT00155532 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa
NCT01538862 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
NCT00442611 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis
NCT05488327 ·Status: UNKNOWN ·Phase: NA
-
A Phase 2 Study With CC-220 in Skin Sarcoidosis
NCT02192489 ·Status: WITHDRAWN ·Phase: PHASE2
-
Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study
NCT03582800 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
NCT06119490 ·Status: RECRUITING ·Phase: EARLY_PHASE1